DR. ANTHONY STEPHEN FAUCI, M.D.
Osteopathic Medicine in Washington, DC

6548055, Apr 15, 2003

Aug 9, 2000

09/635286

H. Clifford Lane - Bethesda MD
Joseph A. Kovacs - Potomac MD
Anthony S. Fauci - Washington DC

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 3820

424 852, 514 44, 514 49, 514885

A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

6190656, Feb 20, 2001

Sep 2, 1997

8/922218

H. Clifford Lane - Bethesda MD
Joseph A. Kovacs - Potomac MD
Anthony S. Fauci - Washington DC

The United States of America as represented by the Department of Health and
Human Services - Washington DC

A61K 4500, A01N 3718, C07K 1455, C12Q 168

424 852

A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

5696079, Dec 9, 1997

May 26, 1995

8/452440

H. Clifford Lane - Bethesda MD
Joseph A. Kovacs - Potomac MD
Anthony S. Fauci - Washington DC

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61K 3820

514 2

A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.

2003018, Sep 25, 2003

Jan 23, 2003

10/351274

H. Lane - Bethesda MD, US
Joseph Kovacs - Potomac MD, US
Anthony Fauci - Washington DC, US

The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services

A61K038/20

424/085200

A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

2009028, Nov 19, 2009

Mar 21, 2008

12/053506

James Arthos - Rockville MD, US
Claudia Cicala - Bethesda MD, US
Anthony S. Fauci - Washington DC, US

A61K 39/395, C07H 21/00, C12N 15/63, C12N 5/00, C12N 5/08, C12N 7/06, A61P 37/04

4241341, 536 234, 4353201, 435325, 435366, 435238, 435375

Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.

7368114, May 6, 2008

Oct 24, 2002

10/493676

James Arthos - Rockville MD, US
Claudia Cicala - Bethesda MD, US
Anthony S. Fauci - Washington DC, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 39/00, A61K 38/00, C12P 21/08

4241921, 530300, 5303873

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

6911527, Jun 28, 2005

Jan 7, 2000

09/869003

Giuseppe Scala - Pozzuoli, IT
Xueni Chen - Ann Arbor MI, US
Oren J. Cohen - Bethesda MD, US
Anthony S. Fauci - Washington DC, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

A61K038/04

530328, 530323, 530324, 530325, 530326, 530327, 530826, 435 5, 435 71, 4241881, 4241991, 4242081

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.